Genmab maintains 2026 revenue guidance at USD 4.33…

Lantheus Reports Results for Quarter Ended September 30 L impact | EARNINGS | Nov 05, 2026, 04:24 PM UTC

Phibro Animal Health Maintains FY2027 Adjusted EPS Outlook at $3.41-$3.59 Phibro Animal Health Maintains FY2027 Adjusted EPS Outlook at $3.41-$3.59 Phibro Animal Health m L impact | EARNINGS | Nov 05, 2026, 04:24 PM UTC

Gildan Activewear Inc. reports results for the quarter ended September 30 - Earnings Summary Gildan Activewear Inc. reports results for the quarter ended September 30 - Earnings Summary Gildan L impact | EARNINGS | Nov 05, 2026, 04:23 PM UTC

CF Industries Sees Robust UAN and Urea Demand Through 1H 2027 CF Industries expects a positive nitrogen pricing trajectory through at least the first half of 2027. L impact | EARNINGS | Nov 05, 2026, 04:22 PM UTC

Enviri 3Q 2026: Revenue $325.03M, EPS $0.09 — 10-Q Summary Enviri’s third-quarter revenue was essentially flat year over year, while earnings improved to a profit from a loss. Higher Harsco Environmental service levels and ecoproduct deman L impact | EARNINGS | Nov 05, 2026, 04:21 PM UTC

Camden National 3Q 2026: Revenue $68.67M, EPS $1.34 — 10-Q Summary Camden National's third-quarter net interest income plus noninterest income rose year over year, while net income increased. Lower funding costs and an improved funding mix lifted L impact | EARNINGS | Nov 05, 2026, 04:21 PM UTC

Genmab maintains 2026 revenue guidance at USD 4.33 billion to USD 4.53 billion

Related stories